Merck’s ‘breakthrough’ hep C combo plays catch-up with promising PhII results

John Carroll

Merck may be playing catch-up in the race to develop the first all-oral treatment for hepatitis C, but it made a good case over the weekend that it has a real contender in the pipeline.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS